Compare SCYX & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | ATCH |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 34.9M |
| IPO Year | 2014 | 2024 |
| Metric | SCYX | ATCH |
|---|---|---|
| Price | $1.00 | $0.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | $1.00 |
| AVG Volume (30 Days) | 427.0K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | $3.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.14 |
| 52 Week High | $1.29 | $1.92 |
| Indicator | SCYX | ATCH |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 64.96 |
| Support Level | $0.65 | $0.25 |
| Resistance Level | $1.29 | $0.28 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 97.94 | 90.96 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.